News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Tom O’Leary

Advertisement

Articles by Tom O’Leary

Relationship-Centric Technology: Improving the Human Experience for Better Engagement

ByTom O’Leary
September 21st 2015

Relationship-centric technology presents a sizable emerging opportunity for sponsors to improve the performance of clinical development, writes Tom O' Leary.

Advertisement

Latest Updated Articles

  • Relationship-Centric Technology: Improving the Human Experience for Better Engagement
    Relationship-Centric Technology: Improving the Human Experience for Better Engagement

    Published: September 21st 2015 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.

2

Amgen Acquires Dark Blue Therapeutics in $840 Million Transaction

3

Nimbus Therapeutics and Eli Lilly Enter $1.3 Billion License Agreement and Research Collaboration for Oral Obesity Treatments

4

Parental Control: Why Pharma’s Strongest Asset May Be Its Parent Brand

5

Ketamine’s Regulatory Reckoning: From Rapid Growth to Enforcement

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us